BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director George B. Abercrombie Sells 74,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director George B. Abercrombie sold 74,000 shares of the firm’s stock in a transaction dated Friday, September 10th. The shares were sold at an average price of $15.09, for a total transaction of $1,116,660.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

George B. Abercrombie also recently made the following trade(s):

  • On Thursday, July 15th, George B. Abercrombie sold 5,000 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $15.69, for a total transaction of $78,450.00.

Shares of BCRX opened at $15.48 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $3.30 and a 12-month high of $18.48. The firm has a 50-day moving average price of $15.90 and a 200 day moving average price of $14.17. The firm has a market capitalization of $2.77 billion, a P/E ratio of -12.90 and a beta of 2.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 270.53% and a negative return on equity of 5,272.40%. The firm had revenue of $49.96 million during the quarter, compared to analysts’ expectations of $31.37 million. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.22 EPS for the current year.

BCRX has been the subject of several research reports. HC Wainwright lifted their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 6th. Cowen boosted their target price on shares of BioCryst Pharmaceuticals from $18.00 to $21.00 and gave the company an “outperform” rating in a research note on Thursday, June 17th. Jefferies Financial Group cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating and set a $19.00 target price for the company. in a research note on Friday, August 6th. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 3rd. They set an “overweight” rating and a $21.00 price objective for the company. Finally, JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, August 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $19.45.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dark Forest Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $30,000. Panagora Asset Management Inc. lifted its position in shares of BioCryst Pharmaceuticals by 500.0% during the second quarter. Panagora Asset Management Inc. now owns 2,910 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 2,425 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $77,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $88,000. Finally, IFP Advisors Inc lifted its position in shares of BioCryst Pharmaceuticals by 44.6% during the second quarter. IFP Advisors Inc now owns 8,822 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 2,723 shares in the last quarter. 58.33% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease.

Further Reading: How dollar cost averaging works

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.